Jiang, Vivian Changying
Hao, Dapeng
Jain, Preetesh
Li, Yijing
Cai, Qingsong
Yao, Yixin
Nie, Lei
Liu, Yang
Jin, Jingling
Wang, Wei
Lee, Heng-Huan
Che, Yuxuan
Dai, Enyu
Han, Guangchun
Wang, Ruiping
Rai, Kunal
Futreal, Andrew
Flowers, Christopher
Wang, Linghua
Wang, Michael
Article History
Received: 7 April 2022
Accepted: 15 September 2022
First Online: 26 September 2022
Declarations
:
: All patient specimens were collected with informed consent and approval from the Institutional Review Board at The University of Texas MD Anderson Cancer Center.
: Not applicable.
: M.W. has received research support from Acerta Pharma, AstraZeneca, BeiGene, BioInvent, Celgene, Genentech, Genmab, Innocare, Janssen, Juno Therapeutics, Kite Pharma, Lilly, Loxo Oncology, Molecular Templates, Oncternal, Pharmacyclics, VelosBio and Vincerx.M.W. received a speaker honorarium from Acerta Pharma, Anticancer Association, AstraZeneca, BeiGene, BGICS, BioInvent, CAHON, Chinese Medical Association, Clinical Care Options, Dava Oncology, Eastern Virginia Medical School, Epizyme, Hebei Cancer Prevention Federation, Imedex, Janssen, Kite Pharma, Leukemia & Lymphoma Society, LLC TS Oncology, Medscape, Miltenyi Biomedicine GmbH, Moffit Cancer Center, Mumbai Hematology Group, Newbridge Pharmaceuticals, OMI, OncLive, Pharmacyclics, Physicians Education Resources (PER), Practice Point Communications (PPC), Scripps and The First Afflicted Hospital of Zhejiang University.M.W. is consultant to AstraZeneca, Bayer Healthcare, BeiGene, BioInvent, CSTone, DTRM Biopharma (Cayman) Limited, Epizyme, Genentech, InnoCare, Janssen, Juno Therapeutics, Kite Pharma, Lilly, Loxo Oncology, Miltenyi Biomedicine GmbH, Oncternal, Pharmacyclics and VelosBio.